Vyome Holdings, Inc (HIND): Nasdaq/NYSE listing notice — ReShape Lifesciences gets Nasdaq bid-price extension until Oct 7, 2024; may reverse split

Vyome Holdings, Inc

Received Nasdaq Staff notice on April 9, 2024, that minimum $1.00 bid price still not met.
Granted additional 180-day compliance period; deadline now October 7, 2024.
If closing bid price ≥ $1.00 for 10 consecutive business days, compliance confirmed.
Failure by Oct 6, 2024 triggers delisting notice; company may appeal to Hearings Panel.
Stockholders approved reverse stock split ratio between 1:10 and 1:60 to remedy deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vyome Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 9, 2024, the Company received a written notice from the Nasdaq Staff that the Company has not regained compliance with the minimum $1.00 bid price requirement. However, the Nasdaq Staff has determined that the Company is eligible for an additional 180 calendar period, or until October 7, 2024, to regain compliance. If at any time during this period the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed. I

View on SEC.gov

95 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-24-004933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.